Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 199,019 shares, a growth of 170.3% from the April 15th total of 73,622 shares. Approximately 2.3% of the shares of the stock are sold short. Based on an average daily volume of 9,855,381 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Capstone Therapeutics presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC bought a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by institutional investors and hedge funds.

Capstone Therapeutics Price Performance

Shares of Capstone Therapeutics stock opened at $0.30 on Friday. The business has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.69. Capstone Therapeutics has a 12 month low of $0.29 and a 12 month high of $3.29. The stock has a market capitalization of $4.33 million, a P/E ratio of -0.08 and a beta of -1.52. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.00 and a quick ratio of 0.26.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.